Your browser doesn't support javascript.
loading
Epidemiological burden of meningococcal disease in Brazil: A systematic literature review and database analysis.
Presa, Jéssica Vespa; de Almeida, Rodrigo Sini; Spinardi, Júlia Regazzini; Cane, Alejandro.
Afiliação
  • Presa JV; Medical and Scientific Affairs, Pfizer Vaccines, Collegeville, PA 19426, USA. Electronic address: Jessica.presa@pfizer.com.
  • de Almeida RS; Medical and Scientific Affairs, Pfizer Vaccines, São Paulo, Brazil. Electronic address: Rodrigo.J.Sini@pfizer.com.
  • Spinardi JR; Medical Affairs, Pfizer Vaccines, São Paulo, Brazil. Electronic address: Julia.Spinardi@pfizer.com.
  • Cane A; Medical and Scientific Affairs Regional Lead, Pfizer Vaccines, Buenos Aires, Argentina. Electronic address: alejandro.cane@pfizer.com.
Int J Infect Dis ; 80: 137-146, 2019 Mar.
Article em En | MEDLINE | ID: mdl-30641200
ABSTRACT

OBJECTIVES:

The aim of this study was to evaluate the epidemiological profile of invasive meningococcal disease (IMD) in Brazil, the first Latin American country to introduce the group C meningococcal conjugate vaccine (included in the vaccination schedule in 2010).

METHODS:

A systematic review was conducted, covering the years 2005-2017, to identify epidemiological information on IMD and Neisseria meningitidis carriers in Brazil. Documents from the Brazilian Ministry of Health and two public databases were analyzed to determine annual incidence rates, absolute numbers of diagnosed cases, serogroups identified, the relative distribution of cases per serogroup, and the case fatality rate (CFR).

RESULTS:

Sixteen studies were selected. The incidence rate ranged from 0.88 to 5.3 cases per 100000 inhabitants per year. According to secondary data, the annual incidence of IMD in 2015 was highest in males <1year old (7.1/100000). The number of diagnosed cases declined significantly over the years. In the literature, IMD showed a CFR from 20.0% to 50.0%, and a higher CFR for serogroup W (17.8%). Secondary data showed an absolute reduction in meningitis-attributable deaths between 2007 and 2015; however, the CFR remained stable (11.1% in 2007 and 8.4% in 2015). In 2015, serogroup W showed the highest CFR (24.1%), followed by serogroups C (19.2%), B (17.7%), and Y (14.3%).

CONCLUSIONS:

Despite a reduction in cases, the CFR remained stable and similar in the different age groups, even for disease caused by different serogroups. The highest CFR was found to be associated with serogroup W.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções Meningocócicas Tipo de estudo: Incidence_studies / Prognostic_studies / Systematic_reviews Limite: Humans País/Região como assunto: America do sul / Brasil Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções Meningocócicas Tipo de estudo: Incidence_studies / Prognostic_studies / Systematic_reviews Limite: Humans País/Região como assunto: America do sul / Brasil Idioma: En Ano de publicação: 2019 Tipo de documento: Article